Pathologically (histologically or cytologically) proven diagnosis of HNSCC of the oral cavity, oropharynx (p16 negative), hypopharynx, or supraglottic larynx
Stage III, IVA or IVB according to the 8th Edition of the American Joint Committee on Cancer (AJCC) guidelines
A candidate for definitive concurrent chemoradiation therapy treatment as determined by investigator and per local guidelines
Participants must have at least 1 target lesion (primary tumor or involved lymph node) per RECIST v.1.1
Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1
You may not be if
Primary tumor originating in the nasopharynx, paranasal sinuses, salivary glands, thyroid gland, parathyroid gland, skin, or unknown primary site
Non-squamous histology
Stages 0, I, II, and IVC HNSCC, loco-regionally recurrent HNSCC, or synchronous second primary HNSCC (within 2 months)
Ineligible to receive platinum-based chemotherapy
Suspected or known allergies, hypersensitivity, or intolerance to JNJ-90301900 or its excipients
Clareo Health | A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
